Abstract
Rasagiline [R(+)-N-propargyl-1-aminoindane] is a selective irreversible inhibitor of MAO-B which is not metabolised to amphetamine-like derivatives. Like deprenyl, when given to rats in a dose selective for inhibition of MAO-B, it does not affect striatal extracellular fluid dopamine levels, but when administered chronically (21 days) it increased striatal microdialysate dopamine without reduction in deaminated metabolites. Similarly to deprenyl, rasagiline (10(-6)M) increased the percentage of tyrosine hydroxylase positive cells in a primary culture of rat fetal mesencephalic cells (6 days in culture). Rasagiline, but not deprenyl, also increased the number of neurons per field in this organotypic culture.
MeSH terms
-
Animals
-
Cells, Cultured
-
Corpus Striatum / drug effects*
-
Corpus Striatum / metabolism
-
Dopamine / biosynthesis
-
Drug Evaluation, Preclinical
-
Humans
-
Indans / pharmacology
-
Indans / therapeutic use*
-
Levodopa / pharmacology
-
Mesencephalon / cytology
-
Mesencephalon / drug effects*
-
Mesencephalon / embryology
-
Microdialysis
-
Mitochondria / drug effects
-
Mitochondria / enzymology
-
Monoamine Oxidase Inhibitors / pharmacology
-
Monoamine Oxidase Inhibitors / therapeutic use*
-
Nerve Tissue Proteins / analysis
-
Neurons / drug effects*
-
Neurons / metabolism
-
Neuroprotective Agents / pharmacology
-
Neuroprotective Agents / therapeutic use*
-
Rats
-
Tyrosine 3-Monooxygenase / analysis
Substances
-
Indans
-
Monoamine Oxidase Inhibitors
-
Nerve Tissue Proteins
-
Neuroprotective Agents
-
rasagiline
-
Levodopa
-
Tyrosine 3-Monooxygenase
-
Dopamine